AD Emerging Therapeutics in 2021 and Beyond
- In:
Clinical Practice
1. No clinically meaningful adverse changes in lab values were found in dupilumab OLE studies in adults or adolescents, supporting that routine lab monitoring is not required.
2. Delgocitinib is a topical pan JAK inhibitor meaning it inhibits JAK1, JAK2, JAK3, and TYK2; it has been fast tracked by the FDA for chronic hand eczema.
3. S1P is a sphingolipid that has been identified as a prominent signaling molecule which regulates keratinocyte function and skin dendritic cells. This process has been found to selectively reduce migration of lymphocytes from the lymph nodes and possibly less the inflammation associated with AD